TOURMALINE BIO INC (TRML)
US89157D1054 - Common Stock
Overall TRML gets a fundamental rating of 3 out of 10. We evaluated TRML against 586 industry peers in the Biotechnology industry. TRML has a great financial health rating, but its profitability evaluates not so good. TRML is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year TRML has reported negative net income.
TRML had a negative operating cash flow in the past year.
In the past 5 years TRML always reported negative net income.
In the past 5 years TRML always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -9.17%, TRML belongs to the top of the industry, outperforming 89.02% of the companies in the same industry.
With an excellent Return On Equity value of -9.30%, TRML belongs to the best of the industry, outperforming 91.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.17% | ||
| ROE | -9.3% | ||
| ROIC | N/A |
ROA(3y)-25.73%
ROA(5y)-27.08%
ROE(3y)-27.09%
ROE(5y)-28.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TRML does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TRML has more shares outstanding than it did 1 year ago.
TRML has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 46.32 indicates that TRML is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 46.32, TRML belongs to the best of the industry, outperforming 96.91% of the companies in the same industry.
TRML has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 46.32 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 62.17 indicates that TRML has no problem at all paying its short term obligations.
TRML's Current ratio of 62.17 is amongst the best of the industry. TRML outperforms 99.83% of its industry peers.
A Quick Ratio of 62.17 indicates that TRML has no problem at all paying its short term obligations.
TRML's Quick ratio of 62.17 is amongst the best of the industry. TRML outperforms 99.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 62.17 | ||
| Quick Ratio | 62.17 |
3. Growth
3.1 Past
TRML shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.61%, which is quite impressive.
EPS 1Y (TTM)71.61%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q89.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
Based on estimates for the next years, TRML will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.36% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.33%
EPS Next 2Y5.96%
EPS Next 3Y-0.15%
EPS Next 5Y13.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
TRML reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRML. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.96%
EPS Next 3Y-0.15%
5. Dividend
5.1 Amount
TRML has a Yearly Dividend Yield of 100.52%, which is a nice return.
The stock price of TRML dropped by -64.74% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
TRML's Dividend Yield is rather good when compared to the industry average which is at 31.61. TRML pays more dividend than 100.00% of the companies in the same industry.
TRML's Dividend Yield is rather good when compared to the S&P500 average which is at 2.32.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 100.52% |
5.2 History
TRML does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y5.96%
EPS Next 3Y-0.15%
TOURMALINE BIO INC
NASDAQ:TRML (5/17/2024, 7:00:01 PM)
After market: 15.04 0 (0%)15.04
+0.04 (+0.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap385.78M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 100.52% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.17% | ||
| ROE | -9.3% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 62.17 | ||
| Quick Ratio | 62.17 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)71.61%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y16.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y